Background: The Pathway Registry evaluated sphenopalatine ganglion (SPG) stimulation for cluster headache (CH). Previously, in a randomized, double-blind, multicenter study (Pathway CH-1), 68% of patients experienced clinically significant improvements. We evaluated longterm therapeutic effectiveness of SPG stimulation.
Background: The Pathway Registry evaluated sphenopalatine ganglion (SPG) stimulation for cluster headache (CH). Previously, in a randomized, double-blind, multicenter study (Pathway CH-1), 68% of patients experienced clinically significant improvements. We evaluated longterm therapeutic effectiveness of SPG stimulation.
Method: Acute pain response following SPG stimulation and attack frequency reduction were analyzed at 12 months following SPG microstimulator insertion. Acute effectiveness is relief/freedom from !moderate pain, or freedom from mild pain. Therapeutic responders achieved acute effectiveness in !50% of attacks by end of stimulation, or !50% attack frequency reduction versus baseline. Patients were similarly evaluated for !75 and !30% therapeutic response.
Results: Through March 2016, 119 patients were enrolled. 80 patients (74 chronic CH, 6 episodic CH) had a microstimulator inserted and progressed through the 12 month study visit (374 AE 31 days post-insertion, range 322-475).
In these 80 patients (59 male, 21 female, age 46 AE 12 years), baseline attack frequency was 24.9 AE 20.8 attacks/ week with severely CH impact (HIT-6: 64.0 AE 6.9). 66% (53/80) were therapeutic responders with a response of !50%. Frequency responders (43/80) reduced attack frequency by 86% (26.5 AE 23.2 to 3.6 AE 6.6 attacks/week, p < 0.001). Acute responders (25/80) achieved effective therapy in 87% of attacks (4212/4863) by end of stimulation. 46% (37/80) of patients experienced a very strong therapeutic response of at least 75%; 75% (61/80) experienced at therapeutic response of at least 30%.
Conclusion: Therapeutic effectiveness of SPG stimulation in chronic medically refractory cluster patients (Pathway CH-1 trial) is confirmed in an open label registry of a large series of cluster patients through 12 months.
